Daiwa Capital Markets America’s Alexion Pharmaceuticals ALXN Stock Holding History

Daiwa Capital Markets America’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$757K	Buy	+5,700	New	+$684K	0.01%	307

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Daiwa Capital Markets America's ALXN Position: Q4 2013 in Review

Daiwa Capital Markets America opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2013: 5,700 shares worth $757K. The stake represents 0.01% of the portfolio and ranks #307 among its holdings.

463 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

Daiwa Capital Markets America held 5,700 shares of Alexion Pharmaceuticals worth $757K as of Q4 2013.
Alexion Pharmaceuticals was a new Daiwa Capital Markets America position in Q4 2013.
Alexion Pharmaceuticals made up 0.01% of Daiwa Capital Markets America's portfolio in Q4 2013, its #307 holding.
463 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on Daiwa Capital Markets America's 13F filing for Q4 2013, filed 13 Feb 2014.